anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a fluid infusion capable of stable coexistence with metals such as calcium, magnesium and trace metals and requiring no pH adjustment by acid, thus excellent in stability, containing a saccharide phosphoric ester salt as phosphorus component. CONSTITUTION:The objective fluid infusion containing 3-65 (pref. 5-10) mmol/l of a saccharide phosphoric ester salt as phosphorus component (e.g. monosaccharide or disaccharide phosphoric ester salt, esp. glucose-1-calcium phosphate. This fluid infusion will not cause precipitation even incorporated with both phosphorus component and inorganic matter, furthermore, requiring no pH adjustment because of the pH buffering ability of the saccharide phosphoric ester; therefore, enabling ready simultaneous administration of phosphorus and inorganic matter with no risk of infectious disease development.
The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
<P>PROBLEM TO BE SOLVED: To provide an Agaricus Blazei Muril polysaccharide protein composition having excellent solubility in water and transparency by low-temperature extraction in which a substance having 40,000 molecular weight is reduced.  <P>SOLUTION: The method for producing the polysaccharide protein composition having high antitumor effects is carried out as follows. An essence of Agaricus Blazei Muril is extracted at 5-70°C with water and concentrated. The resultant concentrate obtained by concentration from the essence is subjected to alcohol precipitation at -10 to -30°C. The formed precipitate is separated, collected and freeze-dried to provide the polysaccharide protein composition.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: In vitro fertilization (IVF) has emerged as a transformative solution for infertility. However, achieving favorable live-birth outcomes remains challenging. Current clinical IVF practices in IVF involve the collection of heterogeneous embryo data through diverse methods, including static images and temporal videos. However, traditional embryo selection methods, primarily reliant on visual inspection of morphology, exhibit variability and are contingent on the experience of practitioners. Therefore, an automated system that can evaluate heterogeneous embryo data to predict the final outcomes of live births is highly desirable.
METHODS: We employed artificial intelligence (AI) for embryo morphological grading, blastocyst embryo selection, aneuploidy prediction, and final live-birth outcome prediction. We developed and validated the AI models using multitask learning for embryo morphological assessment, including pronucleus type on day 1 and the number of blastomeres, asymmetry, and fragmentation of blastomeres on day 3, using 19,201 embryo photographs from 8271 patients. A neural network was trained on embryo and clinical metadata to identify good-quality embryos for implantation on day 3 or day 5, and predict live-birth outcomes. Additionally, a 3D convolutional neural network was trained on 418 time-lapse videos of preimplantation genetic testing (PGT)-based ploidy outcomes for the prediction of aneuploidy and consequent live-birth outcomes.
RESULTS: These two approaches enabled us to automatically assess the implantation potential. By combining embryo and maternal metrics in an ensemble AI model, we evaluated live-birth outcomes in a prospective cohort that achieved higher accuracy than experienced embryologists (46.1% vs. 30.7% on day 3, 55.0% vs. 40.7% on day 5). Our results demonstrate the potential for AI-based selection of embryos based on characteristics beyond the observational abilities of human clinicians (area under the curve: 0.769, 95% confidence interval: 0.709-0.820). These findings could potentially provide a noninvasive, high-throughput, and low-cost screening tool to facilitate embryo selection and achieve better outcomes.
CONCLUSIONS: Our study underscores the AI model's ability to provide interpretable evidence for clinicians in assisted reproduction, highlighting its potential as a noninvasive, efficient, and cost-effective tool for improved embryo selection and enhanced IVF outcomes. The convergence of cutting-edge technology and reproductive medicine has opened new avenues for addressing infertility challenges and optimizing IVF success rates.
An ultrasound imaging system may include a user interface that may be adapted based at least in part on usage data of one or more users. In some examples, the functionality of the soft control or the hard control may be changed. In some examples, the layout or appearance of the soft or hard controls may be changed. In some examples, rarely used controls may be removed from the user interface. In some examples, the user interface may be adapted based on the anatomical feature being imaged. In some examples, the usage data may be analyzed by an artificial intelligence/machine learning model, which may provide output that may be used to adapt the user interface.
Chronic hepatitis C (HCV) is a serious chronic condition in the United States affecting millions of people and is the cause of rates of hepatocellular carcinoma recently doubling in the US. Treatment of hepatitis C is proven to be an effective secondary prevention of liver cancer. Current standard antiviral treatments exclude 70-80% of hepatitis C patients from therapies due to intolerable side effects. Our laboratory efforts identified a potential novel approach to hepatitis C treatment and hepatocellular carcinoma prevention with Quercetin, a heat shock protein inhibitor.

This is a Phase I study evaluating the safety and tolerability of Quercetin in hepatitis C patients who have contraindications to standard antiviral treatment (both treatment naïve patients who decline standard therapy, patients who previously had standard treatments with relapse, as well as those who had intolerable side effects previously). The investigators recently demonstrated that the flavonoid Quercetin inhibits hepatitis C viral production in tissue culture, at least partially through its inhibition of heat shock protein expression. This represents a novel mechanism for treating hepatitis C infection. Quercetin also has low toxicity. These promising characteristics motivate the proposed Phase I study. Patients will be recruited through the UCLA Pfleger Liver Institute and treated on an outpatient basis. Toxicity will be closely monitored and reported. Viral load response will be evaluated as a secondary endpoint. The anticipated total number of patients enrolled in the trial will be 20. All patients will be followed for 8 months after taking this first dose of study medication. Patients exhibiting a viral load response will have extended follow-up, ranging from a total follow-up of 12-24 months, to determine persistence of this response.
<P>PROBLEM TO BE SOLVED: To obtain a safe and low-cost zinc absorption accelerator accelerating the absorption of zinc into bodies because an abnormality in taste and loss of growth are caused by deficiency of zinc absorption, which is a problem in recent years, and to provide a food having accelerating actions on zinc absorption.  <P>SOLUTION: The zinc absorption accelerator is composed of a scallop mantle or a processed product obtained from the scallop mantle as a raw material. The zinc absorption accelerator can be used by ingestion together with a food or formulation in the food. The zinc absorption accelerator, together with the zinc, is preferably formulated in the food. The scallop mantle irreversibly adsorbing the zinc can be utilized as the zinc absorption accelerator or a food material having accelerating effects on the zinc absorption.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PROBLEM TO BE SOLVED: To treat or prevent osteoporosis by administering a polyphosphonic acid salt having a suppressing effect for a bone absorption or parathyroid hormone together with a specific compound such as droloxifene. SOLUTION: This combination therapy for the treatment of osteoporosis is to administer a compound of the formula (R<1> , R<2> are each methyl or ethyl, when both of them are same, and one of them is methyl or ethyl and the other is H or benzyl, when they are different) or medicinally permissible salt thereof together with a polyphosphonic acid salt suppressing a bone resorption or parathyroid hormone. As the medicinally permissible salt, a citric acid salt is suitable. As the polyphosphonic acid, alendronate is preferable. The parathyroid hormone is preferably administered for a period of approximately 3 months to approximately 3 years.  As a kit for the treatment of a low mass state of a bone, a first unit consisting of the compound of the formula of an effective amount with a carrier and a second unit consisting of the parathyroid hormone of an effective amount and a carrier are used by loading them into containers.
BACKGROUND AND QUESTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the total population, and previous studies have already reported the prevalence of AF; however, AF is of special importance in geriatric patients due to demographic changes. Therefore, the aim of this study was to determine how many geriatric patients have a history of AF (prevalence) and how often AF can be newly diagnosed during an inpatient stay (incidence). Additionally, predictive factors for the incidence of AF in geriatric patients are described.
STUDY PARTICIPANTS AND METHODS: In a monocentric prospective observational study from April 2021 to April 2022, all admissions to a geriatric clinic were included in the study. Data collection was carried out using the patients' digital files. As part of the admission routine, all patients had a 12-lead ECG recorded. Additionally, a 24‑h long-term electrocardiogram (LTECG) was used in a subset of patients depending on the clinical need.
RESULTS: A total of 1914 participants were included in the study. At the time of admission, 715 (37.4%) patients had a known history of AF. Of the remaining 1199 patients without a history of AF, AF could be newly detected in 73 cases (6.1%). Multivariate regression analysis identified age > 80 years (odds ratio, OR: 2.3) and heart failure (OR: 3.5) as significant risk factors for the incidence of AF (each p < 0.05).
CONCLUSION: Despite an already high prevalence, AF was newly diagnosed in 6% of patients during the stay at a geriatric clinic. Heart failure and age above 80 years were significantly associated with the presence of AF. This should be taken into account when screening for AF in this patient population.
PURPOSE:A prolonged action complex capable of releasing a physiologically active substance at long intervals, obtained by forming a core including a physiologically  active substance, an interval layer not including it, and an outermost layer including it successively in this order. CONSTITUTION:A physiologically active substance (e.g., testrone) is blended with a vinyl type polymerizable monomer (e.g., hydroxyethyl acrylate) to be supercooled, a natural or synthetic high polymer substance (e.g., polymethyl methacrylate) and a substance system selected from their mixture, to give a blend which is formed into a given shape and processed by a physical operation to give a prolonged action complex. A film consisting of a substance system equal to the above-mentioned substance system is formed on the surface of the prolonged action complex, to form an interval layer having no physiologically active substance. A layer including a physiologically active substance is made on the interval layer. Formation of polylayer is carried out arbitrarily in the order. The release of the physiologically  active substance is carried out periodically.
AIM: A pilot randomised controlled trial assessed the early application of nasal high-flow (NHF) therapy compared with standard oxygen therapy (SOT), in children aged 0 to 16 years presenting to paediatric emergency departments with acute hypoxaemic respiratory failure (AHRF). The study estimated the need to escalate therapy and hospital length of stay in the NHF group compared with SOT. This sub-study then assessed the subsequent cost-effectiveness.
METHODS: A decision tree-based model was developed, alongside the clinical study, to estimate cost-effectiveness, from the healthcare sector perspective. The primary health economics outcome is measured as incremental cost per length of hospital stay avoided. Incremental cost effectiveness ratios (ICER) measuring change in cost per change in length of stay, were obtained for four samples, depending on responder status and obstructive airways disease. These were (1) obstructive and responder, (2) non-obstructive and responder, (3) obstructive and non-responder and (4) non obstructive and non-responder. Bootstrapping of parameters accounted for uncertainty in estimates of cost and outcome.
RESULTS: The ICER for patients randomised to NHF, indicated an additional A$367.20 for a lower hospital length of stay (in days) in the non-obstructive/non-responder sample. In the bootstrap sample, this was found to be cost effective above a willingness to pay threshold of A$10 000. The ICER was A$440.86 in the obstructive/responder sample and A$469.56 in the non-obstructive/responder sample - but both resulted in a longer length of stay. The ICER in the obstructive/non-responder sample was A$52 167.76, also with a longer length of stay, mainly impacted by a small sample of severe cases.
CONCLUSION: As first-line treatment, NHF is unlikely to be cost-effective compared with SOT, but for non-obstructive patients who required escalation in care (non-obstructive non-responder), NHF is likely to be cost-effective if willingness-to-pay per reduced hospital length of stay is more than A$10 000 per patient.
Multiple stigmas related to sexuality, race, and HIV infection negatively impact HIV testing, engagement in HIV care, and consistent viral suppression (VS) among young Black or Latino men who have sex with men and transgender women (YBLMT). At present, few interventions have addressed the effects of intersectional stigma among people living with HIV and HIV affected populations. This study tests whether an online intervention tailored for intersectional stigma amelioration can elicit online social support, promote intervention engagement, and mitigate the impact of multiple stigmas on HIV-related outcomes. This study will recruit and enroll 1,050 young (ages 15-29), racially and ethnically diverse men who have sex with men and transgender women affected by HIV across the United States. Using a HIV-status stratified randomized trial design, participants will be assigned into one of three conditions (information-only control, a researcher-driven social network intervention, or a peer-driven social network intervention). Behavioral assessments will occur at baseline, 3, 6, 9 and 12 months; biomarkers (viral load) are scheduled for baseline, 6 and 12 months. The primary outcome is stratified by HIV status and defined as successful engagement in care (consistent VS for HIV-positive participants and routine testing for HIV-negative participants). The specific aims are: 1) Test whether an online intervention that promotes user-generated content and engagement to address intersectional stigma is associated with improvements in the HIV prevention and care continuum (HIV testing, antiretroviral adherence, VS) as compared to an information-only control arm; 2) Explore whether user engagement, as measured by quantitative and qualitative paradata, mediates the intervention's stigma- and HIV care-related outcomes; and, 3) Examine how changes in intersectional stigma and improvements across the HIV care continuum vary between the researcher-driven vs. peer-driven social network intervention conditions. The research study is innovative given its focus on intersectional stigma as a key target of intervention, and its ability to assess how different kinds of online social network structures influence participants' engagement over time, reduce experiences of intersectional stigma, and improve successful engagement in care. This research addresses a critical need to reduce the effects of multiple stigmas in a priority population using an intervention delivered through a highly appealing, widely-utilized technology. If effective, this form of stigma amelioration via online support can be broadly disseminated to reduce HIV transmission and improve care among YBLMT.
Contact lens sensors have been emerging as point-of-care devices in recent healthcare developments for ocular physiological condition monitoring and diagnosis. Fluorescence sensing technologies have been widely applied in contact lens sensors due to their accuracy, high sensitivity, and specificity. As ascorbic acid (AA) level in tears is closely related to ocular inflammation, a fluorescent contact lens sensor incorporating a BSA-Au nanocluster (NC) probe is developed for in situ tear AA detection. The NCs are firstly synthesized to obtain a fluorescent probe, which exhibits high reusability through the quench/recover (KMnO4/AA) process. The probe is then encapsulated with 15 wt% of poly(vinyl alcohol) (PVA) and 1.5 wt% of citric acid (CA) film, and implemented on a closed microfluidic contact lens sensing region. The laser-ablated microfluidic channel in contact lens sensors allows for tear fluid to flow through the sensing region, enabling an in-situ detection of AA. Meanwhile, a smartphone application accompanied by a customized 3D printed readout box is developed for image caption and algorism to quantitative analysis of AA levels. The contact lens sensor is tested within the readout box and the emission signal is collected through the smartphone camera at room temperature with an achieved LOD of 0.178 mmol L-1 (0.0-1.2 mmol L-1). The operational and storage lifetime is also evaluated to characterize the sensor properties and resulted in 20 h and 10 days, respectively. The reusable AA contact lens sensor is promising to lead to an alternative accessible diagnostic method for ocular inflammation in point-of-care settings.
Intervertebral Disc (IVD) degeneration has been associated with a chronic inflammatory response, but knowledge on the contribution of distinct IVD cells, namely CD44, to the progression of IVD degeneration remains elusive. Here, bovine nucleus pulposus (NP) CD44 cells were sorted and compared by gene expression and proteomics with the negative counterpart. NP cells were then stimulated with IL-1b (10 ng/ml) and dynamics of CD44 gene and protein expression was analyzed upon pro-inflammatory treatment. The results emphasize that CD44 has a multidimensional functional role in IVD metabolism, ECM synthesis and production of neuropermissive factors. CD44 widespread expression in NP was partially associated with CD14 and CD45, resulting in the identification of distinct cell subsets. In conclusion, this study points out CD44 and CD44-based cell subsets as relevant targets in the modulation of the IVD pro-inflammatory/degenerative cascade.
There have not been sufficient numbers of geriatric patients involved in studies utilizing Cenestin to determine whether those over 65 years of age differ from younger subjects in their response to Cenestin.   
In the Women’s Health Initiative Memory Study, including 4,532 women 65 years of age and older, followed for an average of 4 years, 82% (n = 3,729) were 65 to 74 while 18% (n = 803) were 75 and over. Most women (80%) had no prior hormone therapy use. Women treated with conjugated estrogens plus medroxyprogesterone acetate were reported to have a two-fold increase in the risk of developing probable dementia. Alzheimer’s disease was the most common classification of probable dementia in both the conjugated estrogens plus medroxyprogesterone acetate group and the placebo group. Ninety percent of the cases of probable dementia occurred in the 54% of women that were older than 70. (See WARNINGS, Dementia.)
The highly decentralized nature of global health governance presents significant challenges to conceptualizing and systematically measuring the agenda status of diseases, injuries, risks and other conditions contributing to the collective disease burden. An arenas model for global health agenda setting was recently proposed to help address these challenges. Further developing the model, this study aims to advance more robust inquiry into how and why priority levels may vary among the array of stakeholder arenas in which global health agenda setting occurs. We analyse order and the magnitude of changes in priority for eight infectious diseases in four arenas (international aid, scientific research, pharmaceutical industry and news media) over a period of more than two decades in relation to five propositions from scholarship. The diseases vary on burden and prominence in United Nations Sustainable Development Goal 3 for health and well-being, including four with specific indicators for monitoring and evaluation (HIV/AIDS, tuberculosis, malaria, hepatitis) and four without (dengue, diarrhoeal diseases, measles, meningitis). The order of priority did not consistently align with the disease burden or international development goals in any arena. Additionally, using new methods to measure the scale of annual change in resource allocations that are indicative of priority reveals volatility at the disease level in all arenas amidst broader patterns of stability. Insights around long-term patterns of priority within and among arenas are integral to strengthening analyses that aim to identify pivotal causal mechanisms, to clarify how arenas interact, and to measure the effects they produce.
Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
The invention relates to drugs for treating lumbar disc herniation, in particular to a drug for treating the lumbar disc herniation and a preparation method thereof. The drug is formed by taking animal and plant Chinese medicinal herbs as raw materials and solves the problems of being poor in curing effect, curing the symptoms not the disease and the like, of the prior art. The drug comprises the following raw materials in parts by weight: 30-60 parts of rhizoma atractylodis, 50-80 parts of chaenomeles fruit, 50-80 parts of angelica, 50-80 parts of rhizoma dioscoreae, 30-60 parts of dodder seed, 50-80 parts of desertliving cistanche, 30-60 parts of ground beetle, 30-60 parts of dragon's blood, 50-80 parts of radix astragali preparata, 20-50 parts of pangolin, 30-50 parts of hairy deerhorn, 30-60 parts of panax pseudo-ginseng and 50-80 parts of achyranthes root. The preparation method of the drug for treating the lumbar disc herniation comprises the following steps of: firstly, drying the raw materials, crushing the raw materials into fine powder with the grain diameter of 100-200 meshes, and screening; then, mixing according to proportion, then, carrying out germicidal treatment, and evenly mixing to produce medicaments. The medicaments are water pills, the water pills are dried in shade or medicinal powder is directly encapsulated; or the water pills are prepared into honeyed pills by adding honey. The drug for treating the lumbar disc herniation is prepared by adopting purely-natural animals and plants, so that the drug has the advantages of mild nature, no toxic and side effects and adverse reactions and suitability for long-term medications of patients suffering from the lumbar herniation.